AU2013259503B2 - Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors - Google Patents

Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors Download PDF

Info

Publication number
AU2013259503B2
AU2013259503B2 AU2013259503A AU2013259503A AU2013259503B2 AU 2013259503 B2 AU2013259503 B2 AU 2013259503B2 AU 2013259503 A AU2013259503 A AU 2013259503A AU 2013259503 A AU2013259503 A AU 2013259503A AU 2013259503 B2 AU2013259503 B2 AU 2013259503B2
Authority
AU
Australia
Prior art keywords
acid
docosa
hydroxy
inflammatory
spm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013259503A
Other languages
English (en)
Other versions
AU2013259503A1 (en
Inventor
Gerhardus Lucas BANNENBERG
Fernando Moreno Egea
Charles Nicholas SERHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solutex NA LLC
Original Assignee
Solutex NA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013259503(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solutex NA LLC filed Critical Solutex NA LLC
Publication of AU2013259503A1 publication Critical patent/AU2013259503A1/en
Assigned to SOLUTEX NA LLC reassignment SOLUTEX NA LLC Amend patent request/document other than specification (104) Assignors: BANNENBERG, GERHARDUS, Egea, Fernando, SERHAN, CHARLES, SOLUTEX NA LLC
Application granted granted Critical
Publication of AU2013259503B2 publication Critical patent/AU2013259503B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013259503A 2012-05-10 2013-05-09 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors Active AU2013259503B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645281P 2012-05-10 2012-05-10
US61/645,281 2012-05-10
PCT/US2013/040314 WO2013170006A2 (en) 2012-05-10 2013-05-09 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors

Publications (2)

Publication Number Publication Date
AU2013259503A1 AU2013259503A1 (en) 2014-12-18
AU2013259503B2 true AU2013259503B2 (en) 2017-03-16

Family

ID=49551457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013259503A Active AU2013259503B2 (en) 2012-05-10 2013-05-09 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors

Country Status (12)

Country Link
US (6) US10568858B2 (enExample)
EP (2) EP4205546A1 (enExample)
JP (2) JP6370775B2 (enExample)
CN (3) CN116173001A (enExample)
AU (1) AU2013259503B2 (enExample)
CA (1) CA2873055C (enExample)
DK (1) DK2858496T3 (enExample)
ES (1) ES2946109T3 (enExample)
NZ (1) NZ702325A (enExample)
PL (1) PL2858496T3 (enExample)
PT (1) PT2858496T (enExample)
WO (1) WO2013170006A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9902681B2 (en) 2013-05-30 2018-02-27 The Brigham And Women's Hospital, Inc. N-3 immunoresolvents: structures and actions
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP6604529B2 (ja) * 2014-01-29 2019-11-13 岩手県 ヒドロキシエイコサペンタエン酸の取得方法
JP6315536B2 (ja) * 2014-01-29 2018-04-25 岩手県 Ｐｐａｒ活性化剤
TWI725937B (zh) 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
WO2016130522A1 (en) * 2015-02-09 2016-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US9682034B2 (en) 2015-03-10 2017-06-20 Elc Management Llc Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
AU2016370626B2 (en) * 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
EP3570827B1 (en) * 2017-01-18 2025-06-25 Universitat Autònoma de Barcelona Maresin for use in treating multiple sclerosis and amyotrophic lateral sclerosis
WO2019016580A1 (en) 2017-07-20 2019-01-24 Universitat Autonoma De Barcelona MARESINS FOR USE IN THE TREATMENT OF CNS INJURIES
KR101981534B1 (ko) * 2017-09-01 2019-05-23 (주)솔빛피앤에프 프로텍틴 dx를 유효성분으로 함유하는 고지혈증 또는 지방간 질환 예방 또는 치료용 조성물
KR102003153B1 (ko) * 2018-01-17 2019-07-23 연세대학교 산학협력단 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물
CN111989399B (zh) * 2018-04-16 2024-07-12 韩国生命工学研究院 多不饱和脂肪酸的多羟基衍生物的制备方法
CN108578398A (zh) * 2018-06-11 2018-09-28 温州医科大学 巨噬素在制备预防或治疗类风湿性关节炎的药物中的应用
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2019243887A1 (en) 2018-06-22 2019-12-26 Ambiotis Method for restoration of the natural capacity of the body to end inflammation by personalization of the food supplementation and objectification of its effect
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
US11400057B2 (en) 2018-10-19 2022-08-02 University Of Rochester Treatment of vulvar pain
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
WO2020109480A1 (en) * 2018-11-30 2020-06-04 Evonik Operations Gmbh Preparation for use to increase the formation of one or more specialized pro-resolving lipid mediators (spm)
US20220308071A1 (en) * 2019-06-13 2022-09-29 The Regents Of The University Of California Methods and compositions for determination of liver fibrosis
CN110420224A (zh) * 2019-07-25 2019-11-08 江苏华豚药业有限公司 河豚肝油皂化物的应用及其制备方法
CN118252869A (zh) * 2019-08-01 2024-06-28 赢创运营有限公司 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂
US11607623B2 (en) 2019-08-08 2023-03-21 Cornerstone Technologies Llc Dynamic interface system and its application in supercritical fluid extraction and chromatography
GB201913383D0 (en) * 2019-09-17 2019-10-30 Univ London Queen Mary Methods for predicting patient response to DMARDs
KR102870005B1 (ko) * 2019-09-25 2025-10-17 (주)아모레퍼시픽 피부장벽 강화용 조성물
EP4071241A4 (en) * 2019-12-06 2023-10-18 Korea Research Institute of Bioscience and Biotechnology MONO- OR DIHYDROXY DERIVATIVES OF POLY UNSATURATED FATTY ACIDS, METHOD FOR THEIR PRODUCTION AND THEIR USE
KR102256823B1 (ko) * 2019-12-06 2021-05-26 한국생명공학연구원 도코사헥사노엔산 유도체를 함유하는 주름 개선, 아토피피부염 개선 및 피부 장벽 강화용 복합 조성물
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20230273228A1 (en) 2020-07-17 2023-08-31 Solutex Gc, S.L. Diagnostic Method and Compounds for the Treatment of Infections Caused by a Pathogen
WO2022049168A1 (en) * 2020-09-04 2022-03-10 Dsm Ip Assets B.V. 17(s)-hdpa for metabolic-syndrome related disorders
MX2023006157A (es) 2020-12-04 2023-06-08 Chemo Res S L Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.
US20240198254A1 (en) * 2021-04-27 2024-06-20 K.D. Pharma Bexbach Gmbh Method for separating a mixture
EP4329742A4 (en) * 2021-04-29 2025-02-26 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS COMPRISING EPA AND METHODS OF USE THEREOF FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
KR102662544B1 (ko) * 2021-10-19 2024-05-03 서울대학교산학협력단 참문어 추출물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물
WO2023180569A1 (en) 2022-03-25 2023-09-28 Chemo Research , S.L. Specialized pro-resolving lipid mediators for treating long covid-19
CN115466776B (zh) * 2022-09-26 2025-06-27 中国医学科学院基础医学研究所 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用
CN116139122B (zh) * 2023-02-28 2025-11-07 武汉大学人民医院（湖北省人民医院） 消退素d2在制备缓解和/或治疗心肌梗死及其相关疾病的药物中的应用
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物
CN117257787A (zh) * 2023-11-12 2023-12-22 重庆医科大学附属第二医院 巨噬素1在制备预防或治疗自身免疫性葡萄膜炎药物中的应用
WO2025233510A1 (en) 2024-05-10 2025-11-13 Chemo Research, S.L. Specialized pro-resolving lipid mediators for treating depression, anxiety, and/or stress
WO2026017754A1 (en) 2024-07-17 2026-01-22 Universitat Autònoma De Barcelona Maresin formulation
CN121994974B (zh) * 2026-04-09 2026-06-16 深圳保时健生物工程有限公司 微藻油中促炎症消退因子（SPMs）含量的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH01169354A (ja) 1987-12-25 1989-07-04 Hitachi Ltd 超臨界炭酸ガス抽出物の分取方法
US4966876A (en) 1989-08-22 1990-10-30 Viswanatha Sankaran Transesterification of triglycerides
US5133902A (en) 1989-08-22 1992-07-28 Viswanatha Sankaran Transesterification of triglycerides
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
KR100234947B1 (ko) 1997-06-05 1999-12-15 이형도 멀티 탭 고주파 모듈레이터
US6284268B1 (en) 1997-12-10 2001-09-04 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
JP4175698B2 (ja) * 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
US20040176451A1 (en) 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
JPWO2004048497A1 (ja) 2002-11-22 2006-03-30 日本水産株式会社 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP4280158B2 (ja) * 2002-12-27 2009-06-17 富士フイルム株式会社 ドコサヘキサエン酸生産能を有する微生物及びその利用
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
US20090023808A1 (en) * 2007-06-29 2009-01-22 Martek Biosciences Corporation Production and Purification of Esters of Polyunsaturated Fatty Acids
KR101650584B1 (ko) 2007-08-31 2016-08-23 디에스엠 아이피 어셋츠 비.브이. 다중불포화된 지방산 함유 고체 지방 조성물 및 그의 용도 및 생산
ES2569371T3 (es) * 2008-09-16 2016-05-10 The Brigham And Women's Hospital Inc. Compuestos del ácido 7,14-dihidroxidocosahexaenoico
EP2415748A4 (en) 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
US20110071090A1 (en) 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
CL2009001343A1 (es) * 2009-06-02 2009-07-10 Golden Omega S A Proceso de obtencion concentrado de esteres de epa y dha a partir de aceite marino, que comprende agregar al aceite alcali y agua a menos de 100 grados celsius, agregar solvente, separar fase de refinado, agregar acido, separar la fase no acuosa y agregar alcohol y un catalizador a menos de 150 grados celsius, desolventilizar y destilar.
US8479921B2 (en) 2009-12-09 2013-07-09 Amcor Flexibles, Inc. Child resistant blister package
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
EP2607358A4 (en) 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
PH12014501474B1 (en) 2011-12-27 2024-01-19 Nuseed Global Innovation Ltd Processes for producing lipids
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
MX363035B (es) 2013-06-27 2019-03-06 Smartfish As Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento de inflamacion.
RU2685706C2 (ru) 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURPHY, K.J. et al., Asia Pacific Journal of Clinical Nutrition. 2003, Vol. 12, No. 1, pages 50-60 *

Also Published As

Publication number Publication date
US20150126602A1 (en) 2015-05-07
CN110478342A (zh) 2019-11-22
CA2873055C (en) 2023-10-10
CA2873055A1 (en) 2013-11-14
JP6821626B2 (ja) 2021-01-27
EP2858496B1 (en) 2023-04-12
EP2858496A4 (en) 2016-03-23
US11077083B2 (en) 2021-08-03
US20200281883A1 (en) 2020-09-10
US11077084B2 (en) 2021-08-03
CN116173001A (zh) 2023-05-30
JP2015522535A (ja) 2015-08-06
ES2946109T3 (es) 2023-07-12
WO2013170006A3 (en) 2014-01-03
US20180271818A1 (en) 2018-09-27
JP2018193378A (ja) 2018-12-06
US11865096B2 (en) 2024-01-09
US10568858B2 (en) 2020-02-25
JP6370775B2 (ja) 2018-08-08
DK2858496T3 (da) 2023-07-24
NZ702325A (en) 2016-09-30
US11285126B2 (en) 2022-03-29
WO2013170006A2 (en) 2013-11-14
WO2013170006A4 (en) 2014-02-20
PL2858496T3 (pl) 2023-09-11
US20210154163A1 (en) 2021-05-27
US20190201363A1 (en) 2019-07-04
EP4205546A1 (en) 2023-07-05
EP2858496A2 (en) 2015-04-15
CN104684389A (zh) 2015-06-03
EP2858496B9 (en) 2023-11-29
AU2013259503A1 (en) 2014-12-18
US20220175711A1 (en) 2022-06-09
PT2858496T (pt) 2023-07-20

Similar Documents

Publication Publication Date Title
US11865096B2 (en) Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US20200316086A1 (en) Compositions comprising omega-3 fatty acids, 17-hdha and 18-hepe and methods of using same
US11648229B2 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
AU2018420462B2 (en) DHA enriched polyunsaturated fatty acid compositions
AU2023329693B2 (en) Cetoleic acid composition
HK1240966A1 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)